Can TORL’s ixotatug vedotin carve out a new targeted role in recurrent ovarian cancer?
Early ixotatug vedotin and bevacizumab data suggest activity in Claudin 6-positive ovarian cancer, but the small uncontrolled study cannot yet separate ADC efficacy from combination effects.